USA - NASDAQ:EYPT - US30233G2093 - Common Stock
We assign a fundamental rating of 4 out of 10 to EYPT. EYPT was compared to 196 industry peers in the Pharmaceuticals industry. EYPT has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, EYPT is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -58.24% | ||
ROE | -71.29% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 95.14% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 4.52 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8 | ||
Quick Ratio | 7.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
13.39
+0.03 (+0.22%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 17.78 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.75 | ||
P/tB | 3.75 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -58.24% | ||
ROE | -71.29% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 95.14% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 180.84% | ||
Cap/Sales | 6.66% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8 | ||
Quick Ratio | 7.91 | ||
Altman-Z | 4.52 |